



Press Release

Hetero announces the approval from DCGI for the generic version of 'Daclatasvir'

India, Hyderabad, December 14th, 2015: Hetero, one of India's leading generic pharmaceutical companies and one of the world's largest producer of anti-retroviral drugs, today announced that it has received the approval from Drug Controller General of India (DCGI) for the generic version of Daclatasvir tablets (30mg, 60mg). The product in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent in India.

This product is a generic version of Bristol-Myers Squibb's brand 'Daklinza' - approved by US FDA in July 2015. Daclatasvir is one of the direct-acting antivirals for hepatitis C treatment.¹ Research studies indicates that this drug enables the rapid decline of Hepatitis C virus.^{2,3} Daclatasvir is included the World Health Organization's List of Essential medicines.⁴

About Hetero

Hetero is one of India's leading generic pharmaceutical companies and is one of the world's largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. With more than 20 years of expertise in the pharmaceutical industry, Hetero's strategic business areas include APIs, generics and biosimilars. Hetero also offers custom pharmaceutical services to its partners around the world. The company is recognized for its strengths in Research & Development, manufacturing and commercialization of a wide range of products.

Hetero has more than 25 state-of-the-art manufacturing facilities strategically located worldwide. Majority of our facilities have been successfully audited and approved by various regulatory authorities like US-FDA, EU, TGA – Australia, MCC – South Africa and others. Our portfolio includes more than 200 products, encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, etc.

Hetero has a strong global presence in over 120 countries and focusses on making affordable medicines accessible to patients worldwide. For more information on Hetero, please visit www.heteroworld.com

Media Contact:

A Jeyasingh Balakrishnan
Corporate Communications
Hetero Group of Companies
Mobile: +91 9989626541/ +91 9833836185
E mail: jeyasingh.b@heterodrugs.com

REFERENCES

1. Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonna, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G. (2010). "Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect". *Nature* **465** (7294): 96–100. [doi:10.1038/nature08960](https://doi.org/10.1038/nature08960). [PMID 20410884](https://pubmed.ncbi.nlm.nih.gov/20410884/).
2. Bell, Thomas W. (2010). "Drugs for hepatitis C: unlocking a new mechanism of action". *ChemMedChem* **5** (10): 1663–1665. [doi:10.1002/cmdc.201000334](https://doi.org/10.1002/cmdc.201000334). [PMID 20821796](https://pubmed.ncbi.nlm.nih.gov/20821796/).
3. [Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life](#). Guedj, J et al. Proceedings of the National Academy of Sciences. February 19, 2013.
4. http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf